Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Accumulated Expenses (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Accumulated Expenses for 16 consecutive years, with $170426.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 86.43% year-over-year to $170426.0, compared with a TTM value of $170426.0 through Sep 2025, down 86.43%, and an annual FY2024 reading of $247159.0, down 17.29% over the prior year.
  • Accumulated Expenses was $170426.0 for Q3 2025 at China Pharma Holdings, down from $191293.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.3 million in Q3 2024 and bottomed at $110387.0 in Q2 2022.
  • Average Accumulated Expenses over 5 years is $256629.3, with a median of $195264.0 recorded in 2025.
  • The sharpest move saw Accumulated Expenses soared 949.15% in 2024, then plummeted 86.43% in 2025.
  • Year by year, Accumulated Expenses stood at $298452.0 in 2021, then surged by 35.64% to $404807.0 in 2022, then decreased by 26.18% to $298829.0 in 2023, then dropped by 17.29% to $247159.0 in 2024, then plummeted by 31.05% to $170426.0 in 2025.
  • Business Quant data shows Accumulated Expenses for CPHI at $170426.0 in Q3 2025, $191293.0 in Q2 2025, and $195264.0 in Q1 2025.